At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 25 enrolled
Drug / intervention
Trametinib +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Study of Sequential Trametinib and GSK2141795 in Relapsed or Refractory Multiple Myeloma
In Brief
A Phase 2 clinical trial evaluating Laboratory Biomarker Analysis, Pharmacological Study, and 2 other interventions for Recurrent Plasma Cell Myeloma and Refractory Plasma Cell Myeloma. Completed, enrolled 25 participants across 5 sites.
Detailed Summary
This phase II trial studies how well trametinib and Akt inhibitor GSK2141795 work in treating patients with multiple myeloma that has come back (relapsed) or that does not respond to treatment (refractory). Trametinib and Akt inhibitor GSK2141795 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesCanada
Collaborators--
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartOct 2013
First PostedNov 2013
Primary CompletionAug 2019
Study CompletionSep 2020
TodayJul 2026
First PostedNov 21, 2013
Enrollment StartOct 30, 2013
Primary CompletionAug 31, 2019
Study CompletionSep 28, 2020
TodayJul 2, 2026
Enrollment to primary: 5.8 yearsPosted 12.6 years ago
Interventions
Laboratory Biomarker Analysisother
Correlative studies
Pharmacological Studyother
Correlative studies
Trametinibdrug
Given PO
Uprosertibdrug
Given PO